Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

We report 5-year follow-up of a multicenter phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of mantle cell lymphoma (MCL). The regimen includes induction and maintenance with the LR doublet. Treatment was continuous until progression, with optional discontinuation after 3 year...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Ruan, Jia, Martin, Peter, Christos, Paul, Cerchietti, Leandro, Tam, Wayne, Shah, Bijal, Schuster, Stephen J., Rodriguez, Amelyn, Hyman, David, Calvo-Vidal, Maria Nieves, Smith, Sonali M., Svoboda, Jakub, Furman, Richard R., Coleman, Morton, Leonard, John P.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2018
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6634960/
https://ncbi.nlm.nih.gov/pubmed/30181173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-859769
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items